Annual Drug Patent Expirations for SINGULAIR
Singulair is a drug marketed by Organon and is included in three NDAs. There is one patent protecting this drug and two Paragraph IV challenges.
Drug patent litigation for SINGULAIR.
This drug has twenty-five patent family members in twenty-five countries.
The generic ingredient in SINGULAIR is montelukast sodium. Additional details are available on the montelukast sodium profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
